NCT/Study#

NCT03712202 /

COH18157

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: